#USA #San Diego #Tinostamustine #Knoa Pharma #sunobinop

Knoa Pharma to Present at BIO International Convention 2026

Knoa Pharma LLC, a pharmaceutical company focused on public health, is gearing up to present its promising pipeline assets at the prestigious BIO International Convention 2026, scheduled for June 22-25 in San Diego, California. This event, a cornerstone of the biotechnology industry, will provide Knoa Pharma the opportunity to connect with potential partners and stakeholders while sharing insights regarding its investigational therapeutics.

Scheduled for June 23 at 10:30 a.m. PT in Theatre 1, the presentation will underscore the company's commitment to advancing treatment options. Knoa Pharma is particularly looking to foster collaborations aimed at developing therapies for multiple health challenges, spanning areas such as genitourinary disorders, substance use disorders, and oncology.

Two notable assets will take center stage: tinostamustine and sunobinop.

Tinostamustine

Tinostamustine is a pioneering investigational drug distinguished by its dual action—combining DNA alkylating activity and HDAC inhibition within a single molecular framework. This innovative approach positions it as a potential first-line treatment for glioblastoma (GBM), one of the most aggressive forms of brain cancer. Recent Phase 1 trials have revealed its promising efficacy when used as an adjunct to standard chemoradiation, showcasing particular promise in tough-to-treat, newly diagnosed patients.

Significantly, tinostamustine has gained orphan drug designation from the FDA and is on track to be the first new pharmacological option for GBM in over two decades. Additionally, it is currently integrated into the GBM AGILE study—a pivotal seamless Phase 2/3 clinical research effort facilitating the evaluation of multiple therapies simultaneously against a shared control arm.

This innovative study structure allows the accumulation of comprehensive data that could pave the way for new drug applications and regulatory approvals by the U.S. FDA and global health authorities.

Sunobinop

Conversely, sunobinop emerges as a first-in-class nociceptin receptor agonist, which is under investigation for several conditions including alcohol use disorder (AUD), interstitial cystitis/bladder pain syndrome (IC/BPS), and overactive bladder (OAB). It is particularly noteworthy for its unique ability to address several dimensions of AUD, including cravings and consumption patterns, along with sleep disturbances, marking it as a potentially groundbreaking treatment option that could redefine standards of care in this area.

In relation to OAB and IC/BPS, sunobinop represents an innovative approach, directly targeting bladder sensory nerves to manage urination patterns and alleviate pain, further addressing nocturia issues—conditions that currently suffer from significant unmet medical needs.

Commitment to Public Health

Dr. Julie Ducharme, Chief Scientific Officer at Knoa Pharma, emphasized, “Our approach is grounded in rigorous R&D and a profound exploration of disease biology to design revolutionary therapies for patients grappling with complex and underserved conditions.” She expressed enthusiasm for future collaborations that align with this vision.

Echoing this sentiment, David Saussy, Head of Licensing and Business Development, noted, “The BIO International Convention offers a platform to highlight our promising pipeline assets that strive to meet significant medical needs.”

Knoa Pharma invites interested parties to engage in discussions during the convention, with the prospect of fostering partnerships that align with its mission of delivering innovative medical solutions.

Conclusion

As the BIO International Convention approaches, Knoa Pharma stands ready to unveil therapies that could significantly reshape treatment landscapes for complex medical conditions. Their commitment to public health and innovative solutions showcases the potential for meaningful advancements in patient care. For those interested in learning more about Knoa Pharma's pipeline, further information can be accessed by reaching out via their convention booth or through dedicated communication channels provided during the event.